| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 44 | 2025 | 1051 | 3.310 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 13 | 2017 | 306 | 1.040 |
Why?
|
| Cystic Fibrosis | 5 | 2022 | 121 | 0.990 |
Why?
|
| Anti-Asthmatic Agents | 5 | 2025 | 93 | 0.770 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2025 | 295 | 0.720 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2013 | 76 | 0.580 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2017 | 133 | 0.560 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2018 | 57 | 0.560 |
Why?
|
| Aminophenols | 1 | 2018 | 4 | 0.560 |
Why?
|
| Benzodioxoles | 1 | 2018 | 15 | 0.550 |
Why?
|
| Quinolones | 1 | 2018 | 57 | 0.530 |
Why?
|
| Aminopyridines | 1 | 2018 | 49 | 0.530 |
Why?
|
| Bronchodilator Agents | 5 | 2021 | 70 | 0.480 |
Why?
|
| Bronchi | 8 | 2015 | 234 | 0.450 |
Why?
|
| Nasal Mucosa | 9 | 2024 | 196 | 0.440 |
Why?
|
| Glucocorticoids | 4 | 2019 | 369 | 0.430 |
Why?
|
| DNA Methylation | 5 | 2024 | 702 | 0.420 |
Why?
|
| Bronchiectasis | 3 | 2024 | 14 | 0.410 |
Why?
|
| Hospitalization | 8 | 2024 | 946 | 0.380 |
Why?
|
| Patient Education as Topic | 5 | 2016 | 378 | 0.350 |
Why?
|
| Adult | 52 | 2024 | 28636 | 0.340 |
Why?
|
| Patient Selection | 3 | 2021 | 708 | 0.340 |
Why?
|
| Health Care Coalitions | 1 | 2011 | 9 | 0.340 |
Why?
|
| Community Health Planning | 1 | 2011 | 22 | 0.340 |
Why?
|
| Administration, Inhalation | 10 | 2021 | 203 | 0.340 |
Why?
|
| Salmeterol Xinafoate | 2 | 2021 | 16 | 0.330 |
Why?
|
| Fluticasone | 2 | 2021 | 31 | 0.330 |
Why?
|
| Male | 60 | 2025 | 45792 | 0.330 |
Why?
|
| Muscle, Smooth | 6 | 2015 | 358 | 0.330 |
Why?
|
| Humidity | 10 | 2008 | 94 | 0.330 |
Why?
|
| Forced Expiratory Volume | 8 | 2018 | 136 | 0.320 |
Why?
|
| Humans | 77 | 2025 | 95992 | 0.310 |
Why?
|
| Female | 57 | 2025 | 49980 | 0.300 |
Why?
|
| Mitogens | 3 | 1999 | 60 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2020 | 109 | 0.290 |
Why?
|
| Lung | 10 | 2017 | 1380 | 0.280 |
Why?
|
| Small-Area Analysis | 1 | 2007 | 7 | 0.270 |
Why?
|
| Microbiota | 3 | 2019 | 425 | 0.270 |
Why?
|
| Respiratory System | 2 | 2019 | 120 | 0.270 |
Why?
|
| Middle Aged | 35 | 2024 | 28299 | 0.250 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2015 | 358 | 0.250 |
Why?
|
| Hyperoxia | 3 | 1995 | 37 | 0.250 |
Why?
|
| Metered Dose Inhalers | 3 | 2016 | 33 | 0.240 |
Why?
|
| Urban Health | 2 | 2011 | 55 | 0.230 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 555 | 0.230 |
Why?
|
| Chicago | 8 | 2019 | 1505 | 0.230 |
Why?
|
| Ozone | 1 | 2025 | 12 | 0.230 |
Why?
|
| Nitrogen Dioxide | 1 | 2025 | 19 | 0.230 |
Why?
|
| HLA-G Antigens | 2 | 2017 | 52 | 0.220 |
Why?
|
| Hot Temperature | 7 | 2008 | 221 | 0.220 |
Why?
|
| Health Status Disparities | 1 | 2007 | 221 | 0.220 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2024 | 9 | 0.210 |
Why?
|
| Air | 6 | 2008 | 63 | 0.210 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2024 | 26 | 0.210 |
Why?
|
| Eosinophils | 3 | 2019 | 196 | 0.210 |
Why?
|
| Particulate Matter | 1 | 2025 | 124 | 0.200 |
Why?
|
| Smoking | 3 | 2017 | 651 | 0.200 |
Why?
|
| Child | 12 | 2025 | 7621 | 0.200 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2016 | 62 | 0.200 |
Why?
|
| Nose | 4 | 2008 | 96 | 0.200 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2019 | 65 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 2474 | 0.190 |
Why?
|
| MicroRNAs | 2 | 2021 | 591 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 1533 | 0.190 |
Why?
|
| Biomedical Research | 2 | 2019 | 442 | 0.190 |
Why?
|
| Nasal Cavity | 5 | 2004 | 94 | 0.190 |
Why?
|
| Catheter Ablation | 3 | 2015 | 365 | 0.180 |
Why?
|
| Adolescent | 13 | 2025 | 9878 | 0.180 |
Why?
|
| Neutrophils | 4 | 2019 | 326 | 0.180 |
Why?
|
| Interleukin-33 | 1 | 2021 | 28 | 0.180 |
Why?
|
| Child, Preschool | 8 | 2025 | 3969 | 0.170 |
Why?
|
| Otolaryngology | 1 | 2022 | 56 | 0.170 |
Why?
|
| Cross-Over Studies | 9 | 2025 | 398 | 0.170 |
Why?
|
| Gene Expression Regulation | 4 | 2024 | 2059 | 0.170 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 107 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2885 | 0.160 |
Why?
|
| Epithelial Cells | 4 | 2021 | 704 | 0.160 |
Why?
|
| Social Class | 1 | 2021 | 145 | 0.160 |
Why?
|
| Spirometry | 3 | 2017 | 78 | 0.160 |
Why?
|
| Health Planning | 1 | 1999 | 18 | 0.150 |
Why?
|
| Minority Groups | 1 | 2021 | 154 | 0.150 |
Why?
|
| Electronic Prescribing | 1 | 2019 | 10 | 0.150 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 27 | 0.150 |
Why?
|
| Sinusitis | 1 | 2022 | 222 | 0.150 |
Why?
|
| Cross-Sectional Studies | 8 | 2017 | 1880 | 0.150 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 308 | 0.150 |
Why?
|
| Registries | 1 | 2024 | 998 | 0.150 |
Why?
|
| Fungi | 1 | 2019 | 67 | 0.150 |
Why?
|
| Aged | 18 | 2024 | 20927 | 0.140 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 301 | 0.140 |
Why?
|
| Th2 Cells | 1 | 2019 | 151 | 0.140 |
Why?
|
| Bronchoscopy | 4 | 2015 | 175 | 0.140 |
Why?
|
| Epistasis, Genetic | 1 | 2019 | 92 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 547 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2019 | 281 | 0.130 |
Why?
|
| Gene Expression | 2 | 2018 | 1319 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 87 | 0.130 |
Why?
|
| Sputum | 2 | 2017 | 36 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 249 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 935 | 0.130 |
Why?
|
| Self Care | 3 | 2016 | 170 | 0.120 |
Why?
|
| Respiratory System Agents | 1 | 2016 | 7 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 128 | 0.120 |
Why?
|
| Intention | 1 | 2016 | 52 | 0.120 |
Why?
|
| Smokers | 1 | 2016 | 55 | 0.120 |
Why?
|
| Bacteria | 2 | 2017 | 516 | 0.120 |
Why?
|
| United States | 10 | 2024 | 7785 | 0.120 |
Why?
|
| Community Health Workers | 2 | 2006 | 37 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2016 | 239 | 0.110 |
Why?
|
| CpG Islands | 3 | 2022 | 169 | 0.110 |
Why?
|
| International Classification of Diseases | 2 | 2014 | 68 | 0.110 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 1766 | 0.110 |
Why?
|
| Prednisone | 1 | 2015 | 252 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1275 | 0.110 |
Why?
|
| Pentoxifylline | 1 | 1994 | 7 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 1999 | 468 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 1096 | 0.110 |
Why?
|
| Pregnenediones | 1 | 2014 | 8 | 0.110 |
Why?
|
| Air Pressure | 1 | 1994 | 7 | 0.110 |
Why?
|
| Body Temperature | 3 | 2005 | 133 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2014 | 35 | 0.100 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2014 | 22 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2014 | 94 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 2495 | 0.100 |
Why?
|
| Disease Progression | 2 | 2024 | 1561 | 0.100 |
Why?
|
| Young Adult | 7 | 2021 | 7034 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2017 | 373 | 0.100 |
Why?
|
| Quality of Life | 3 | 2022 | 1816 | 0.100 |
Why?
|
| Vitamins | 1 | 2014 | 86 | 0.100 |
Why?
|
| Adalimumab | 1 | 2014 | 92 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2016 | 272 | 0.100 |
Why?
|
| Respiratory Mechanics | 1 | 1994 | 114 | 0.100 |
Why?
|
| Phenotype | 4 | 2022 | 2575 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 107 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 216 | 0.100 |
Why?
|
| Environmental Exposure | 2 | 2025 | 356 | 0.090 |
Why?
|
| Health Education | 2 | 2006 | 107 | 0.090 |
Why?
|
| Patient Care Management | 1 | 2012 | 30 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2019 | 259 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 96 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 56 | 0.090 |
Why?
|
| Nasal Provocation Tests | 3 | 2001 | 129 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 848 | 0.090 |
Why?
|
| Trachea | 3 | 1999 | 293 | 0.090 |
Why?
|
| Chest Wall Oscillation | 1 | 2011 | 5 | 0.090 |
Why?
|
| Skin Temperature | 2 | 2003 | 16 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1029 | 0.090 |
Why?
|
| Clinical Coding | 1 | 2011 | 23 | 0.090 |
Why?
|
| Community Pharmacy Services | 1 | 2011 | 6 | 0.090 |
Why?
|
| Drug Utilization Review | 1 | 2011 | 14 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 6 | 1995 | 1267 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2014 | 645 | 0.080 |
Why?
|
| Cytokines | 3 | 2021 | 871 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2011 | 422 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2011 | 133 | 0.080 |
Why?
|
| Quantitative Trait Loci | 3 | 2020 | 632 | 0.080 |
Why?
|
| Air Pollution, Indoor | 1 | 2011 | 80 | 0.080 |
Why?
|
| Patient Participation | 1 | 2012 | 241 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2024 | 1962 | 0.080 |
Why?
|
| Rhinitis, Allergic, Seasonal | 5 | 2001 | 179 | 0.080 |
Why?
|
| Inpatients | 1 | 2012 | 348 | 0.080 |
Why?
|
| Health Services Research | 1 | 2010 | 148 | 0.080 |
Why?
|
| Inflammation | 1 | 2015 | 1063 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2015 | 2603 | 0.070 |
Why?
|
| Prevalence | 3 | 2011 | 1355 | 0.070 |
Why?
|
| Cell Division | 4 | 1999 | 701 | 0.070 |
Why?
|
| Acute Disease | 4 | 2012 | 859 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2019 | 4690 | 0.070 |
Why?
|
| Genotype | 3 | 2020 | 1883 | 0.070 |
Why?
|
| Phenoxybenzamine | 2 | 2005 | 15 | 0.070 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2005 | 31 | 0.070 |
Why?
|
| Perception | 1 | 2009 | 185 | 0.070 |
Why?
|
| Airway Obstruction | 1 | 2009 | 117 | 0.070 |
Why?
|
| Foot | 3 | 2003 | 59 | 0.070 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 56 | 0.070 |
Why?
|
| Risk Factors | 3 | 2022 | 5992 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 7224 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2018 | 3115 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2019 | 1792 | 0.070 |
Why?
|
| Rats | 6 | 1995 | 4155 | 0.060 |
Why?
|
| Linear Models | 3 | 2017 | 438 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2017 | 74 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2007 | 163 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 218 | 0.060 |
Why?
|
| Mutation | 1 | 2018 | 4374 | 0.060 |
Why?
|
| Water | 2 | 2005 | 307 | 0.060 |
Why?
|
| Incidence | 3 | 2012 | 1723 | 0.060 |
Why?
|
| Algorithms | 2 | 2011 | 2018 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 1999 | 2928 | 0.060 |
Why?
|
| Olfactory Mucosa | 1 | 2005 | 33 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2005 | 104 | 0.060 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2024 | 8 | 0.050 |
Why?
|
| Ipratropium | 2 | 2003 | 18 | 0.050 |
Why?
|
| Medicaid | 1 | 2007 | 260 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1018 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1966 | 0.050 |
Why?
|
| Research | 1 | 2005 | 265 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2004 | 96 | 0.050 |
Why?
|
| Budesonide | 1 | 2004 | 46 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 1982 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2005 | 151 | 0.050 |
Why?
|
| Rhinitis, Allergic, Perennial | 2 | 2001 | 81 | 0.050 |
Why?
|
| Fibronectins | 1 | 2024 | 100 | 0.050 |
Why?
|
| Air Pollutants | 1 | 2025 | 109 | 0.050 |
Why?
|
| Cell Movement | 2 | 1999 | 816 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1273 | 0.050 |
Why?
|
| Protein C | 1 | 2003 | 7 | 0.050 |
Why?
|
| Mothers | 2 | 2022 | 155 | 0.050 |
Why?
|
| Reflex | 1 | 2003 | 81 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2014 | 297 | 0.050 |
Why?
|
| Recurrence | 3 | 2011 | 1231 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 1995 | 1014 | 0.050 |
Why?
|
| Temperature | 2 | 2001 | 432 | 0.050 |
Why?
|
| Cell Count | 2 | 1999 | 202 | 0.050 |
Why?
|
| Adult Children | 1 | 2022 | 14 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 38 | 0.050 |
Why?
|
| Bronchial Provocation Tests | 2 | 1999 | 25 | 0.050 |
Why?
|
| Japan | 1 | 2022 | 313 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 647 | 0.050 |
Why?
|
| Allergens | 2 | 2000 | 191 | 0.050 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2001 | 7 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2005 | 271 | 0.040 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2021 | 20 | 0.040 |
Why?
|
| Supine Position | 1 | 2001 | 34 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 905 | 0.040 |
Why?
|
| Histamine | 1 | 2001 | 124 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 1999 | 66 | 0.040 |
Why?
|
| Ceftizoxime | 1 | 2001 | 3 | 0.040 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 20 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 321 | 0.040 |
Why?
|
| Ribonucleases | 1 | 2001 | 97 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 491 | 0.040 |
Why?
|
| Hemolysis | 1 | 2001 | 63 | 0.040 |
Why?
|
| Transcriptome | 2 | 2017 | 766 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1006 | 0.040 |
Why?
|
| Oxygen | 3 | 1995 | 781 | 0.040 |
Why?
|
| Animals | 9 | 2021 | 28901 | 0.040 |
Why?
|
| Antigens | 1 | 2001 | 231 | 0.040 |
Why?
|
| Infant | 3 | 2019 | 3359 | 0.040 |
Why?
|
| Body Temperature Regulation | 1 | 2000 | 60 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2004 | 460 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2025 | 9228 | 0.040 |
Why?
|
| Reaction Time | 1 | 2001 | 323 | 0.040 |
Why?
|
| Phosphorylation | 2 | 1999 | 1156 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 240 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 372 | 0.040 |
Why?
|
| Consumer Health Informatics | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 1999 | 85 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 789 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2003 | 298 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 213 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 211 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1999 | 329 | 0.040 |
Why?
|
| Administration, Intranasal | 3 | 2005 | 140 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 342 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1999 | 224 | 0.040 |
Why?
|
| Comorbidity | 1 | 2022 | 1017 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 98 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2020 | 481 | 0.040 |
Why?
|
| Sepsis | 1 | 2003 | 389 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 189 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 317 | 0.040 |
Why?
|
| Chromatin | 1 | 2021 | 445 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 996 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 1157 | 0.030 |
Why?
|
| Health Information Exchange | 1 | 2017 | 12 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1642 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1999 | 303 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2012 | 819 | 0.030 |
Why?
|
| Self Administration | 1 | 2016 | 76 | 0.030 |
Why?
|
| Metabolome | 1 | 2017 | 63 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 102 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 152 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 2016 | 39 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 253 | 0.030 |
Why?
|
| Cough | 1 | 2016 | 57 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 197 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 93 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 202 | 0.030 |
Why?
|
| Survival Analysis | 1 | 1999 | 1541 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 626 | 0.030 |
Why?
|
| Dyspnea | 1 | 2016 | 87 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2017 | 281 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2019 | 2611 | 0.030 |
Why?
|
| Health Literacy | 1 | 2016 | 77 | 0.030 |
Why?
|
| Hand Strength | 1 | 1995 | 63 | 0.030 |
Why?
|
| Checklist | 1 | 2016 | 73 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2015 | 112 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2015 | 88 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 435 | 0.030 |
Why?
|
| Biopsy | 2 | 2015 | 1210 | 0.030 |
Why?
|
| Urban Population | 2 | 2006 | 240 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 721 | 0.030 |
Why?
|
| S Phase | 1 | 1994 | 64 | 0.030 |
Why?
|
| Firearms | 1 | 1995 | 79 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 1158 | 0.030 |
Why?
|
| Poverty | 2 | 2006 | 196 | 0.030 |
Why?
|
| Tantalum | 1 | 1994 | 5 | 0.030 |
Why?
|
| Surface Tension | 1 | 1994 | 9 | 0.030 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 1994 | 10 | 0.030 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1994 | 77 | 0.030 |
Why?
|
| Child Development | 1 | 1995 | 174 | 0.030 |
Why?
|
| Genome, Human | 1 | 2019 | 823 | 0.030 |
Why?
|
| Macrolides | 1 | 2013 | 31 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 487 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1995 | 180 | 0.020 |
Why?
|
| Fatigue | 1 | 2014 | 186 | 0.020 |
Why?
|
| Analysis of Variance | 3 | 2001 | 909 | 0.020 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2012 | 20 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2013 | 94 | 0.020 |
Why?
|
| Airway Management | 1 | 2013 | 48 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2013 | 63 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2012 | 10307 | 0.020 |
Why?
|
| Psychometrics | 1 | 2014 | 340 | 0.020 |
Why?
|
| Mental Health | 1 | 2014 | 202 | 0.020 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2012 | 7 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 686 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 378 | 0.020 |
Why?
|
| Time Factors | 3 | 2014 | 5593 | 0.020 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 90 | 0.020 |
Why?
|
| Immersion | 2 | 2003 | 22 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2012 | 64 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1014 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 157 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 66 | 0.020 |
Why?
|
| Radiography | 1 | 1994 | 823 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1995 | 776 | 0.020 |
Why?
|
| Social Behavior | 1 | 2014 | 309 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 570 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1994 | 1319 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2012 | 200 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2012 | 187 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 458 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 229 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1931 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 333 | 0.020 |
Why?
|
| Sleep | 1 | 2014 | 461 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 257 | 0.020 |
Why?
|
| Respiratory Care Units | 1 | 2009 | 4 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 381 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 983 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2498 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 372 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1425 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2010 | 485 | 0.020 |
Why?
|
| Models, Biological | 1 | 1994 | 1810 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1819 | 0.020 |
Why?
|
| Length of Stay | 1 | 2010 | 835 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1997 | 3581 | 0.020 |
Why?
|
| Housing | 1 | 2006 | 50 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2009 | 363 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2860 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3922 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2005 | 35 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 1995 | 84 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 640 | 0.010 |
Why?
|
| Epithelium | 2 | 1994 | 322 | 0.010 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 30 | 0.010 |
Why?
|
| Lidocaine | 1 | 2003 | 67 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 197 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2003 | 99 | 0.010 |
Why?
|
| Pancreas Transplantation | 1 | 2003 | 105 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 84 | 0.010 |
Why?
|
| Eosinophil Granule Proteins | 1 | 2001 | 20 | 0.010 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2001 | 7 | 0.010 |
Why?
|
| Nasal Lavage Fluid | 1 | 2001 | 26 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1176 | 0.010 |
Why?
|
| Adsorption | 1 | 2001 | 54 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2001 | 127 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2001 | 151 | 0.010 |
Why?
|
| Air Conditioning | 1 | 2001 | 6 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 2001 | 89 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 311 | 0.010 |
Why?
|
| Acoustics | 1 | 2001 | 51 | 0.010 |
Why?
|
| Leukocytes | 1 | 2001 | 213 | 0.010 |
Why?
|
| Random Allocation | 1 | 2001 | 321 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2001 | 127 | 0.010 |
Why?
|
| Skin Tests | 1 | 1999 | 46 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 1999 | 67 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1999 | 217 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 1999 | 72 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1999 | 105 | 0.010 |
Why?
|
| Colforsin | 1 | 1999 | 75 | 0.010 |
Why?
|
| Nasopharynx | 1 | 1999 | 51 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 1999 | 38 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 266 | 0.010 |
Why?
|
| Respiration | 1 | 2000 | 281 | 0.010 |
Why?
|
| DNA | 2 | 1995 | 1329 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 401 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 692 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1999 | 796 | 0.010 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1997 | 47 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 882 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2003 | 1201 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 267 | 0.010 |
Why?
|
| Motor Skills | 1 | 1995 | 80 | 0.010 |
Why?
|
| Blood | 1 | 1995 | 69 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1994 | 58 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1995 | 103 | 0.010 |
Why?
|
| Airway Resistance | 1 | 1994 | 71 | 0.010 |
Why?
|
| Aerosols | 1 | 1994 | 48 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1994 | 67 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1995 | 116 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1994 | 180 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 488 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1995 | 340 | 0.010 |
Why?
|
| Body Weight | 1 | 1994 | 460 | 0.010 |
Why?
|
| Age Factors | 1 | 1994 | 1959 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1995 | 2088 | 0.000 |
Why?
|